Infocom Corporation, a provider of digital health and IT solutions, has launched DigiPro EPPV, a new electronic platform designed to streamline Early Post-Marketing Phase Vigilance (EPPV) processes for pharmaceutical companies in Japan. The system enables faster, more efficient monitoring of drug safety in the early stages after market release.

Enhancing Pharmacovigilance Through Digital Innovation

DigiPro EPPV offers key features such as:

  • Real-time tracking of adverse event reports

  • Centralized data collection and analysis

  • Automated reporting tools aligned with Japan’s EPPV regulatory requirements

The platform is aimed at supporting pharmaceutical manufacturers in complying with Japan’s mandatory early-phase drug safety monitoring guidelines more efficiently and accurately.

Supporting Safer, Smarter Drug Launches

By digitizing EPPV activities, Infocom’s solution:

  • Reduces administrative burden on safety and regulatory teams

  • Enhances traceability and responsiveness during the critical early-use period

  • Facilitates better collaboration between medical representatives and pharmacovigilance departments

Executive Commentary

A spokesperson from Infocom stated:
“DigiPro EPPV represents a significant step toward digital transformation in pharmacovigilance. We’re committed to helping our clients ensure the safe and responsible use of new medicines from day one.”

đŸ‘‰ Read the full analysis at- Infocom Unveils DigiPro EPPV for Early Drug Monitoring

 

đŸ‘‰ Subscribe us IT Business Today

 

https://itbusinesstoday.com/